Autonomix Medical, Inc. has entered into a warrant inducement agreement with an investor for the immediate exercise of outstanding warrants, a move expected to generate approximately $2.6 million in gross proceeds. The agreement involves the exercise of November 2025 Warrants to purchase 428,731 shares of common stock at an amended exercise price of $6.00 per share. The transaction is slated to close on or about July 15, 2026, pending customary conditions.

Transaction Details

The investor has agreed to exercise the outstanding November 2025 Warrants, which were originally issued on November 19, 2025. The resale of the shares issuable upon exercise is registered under an effective registration statement on Form S-3 (File No. 333-291825). Maxim Group LLC acted as the warrant inducement agent and financial advisor for the transaction.

New Warrants Issued

As consideration for the immediate cash exercise, Autonomix Medical agreed to issue unregistered Series D-1 and Series D-2 warrants to the investor. These new warrants allow the purchase of an aggregate of 428,731 shares each, with an exercise price of $5.75 per share. The warrants are exercisable immediately upon issuance and will expire five and a half years from the date of issuance. The company intends to file a registration statement with the Securities and Exchange Commission to cover the resale of shares issuable upon exercise of the new warrants.

Key Terms of the Agreement

The new warrants are being offered in a private placement pursuant to an exemption from the registration requirements of the Securities Act of 1933. The shares issuable upon their exercise have not been registered under the 1933 Act and may not be offered or sold in the United States absent registration or an applicable exemption.

Autonomix Medical, Inc. has strengthened its global intellectual property position with the grant of Canadian Patent No. 3,158,197, titled "Endoscopic Sympathectomy Systems and Methods." The patent, issued on July 13, 2026, covers technologies for real-time nerve sensing, mapping, and physiological monitoring. This addition expands Autonomix's portfolio to 112 issued or pending patent applications worldwide, reinforcing its competitive edge in the multi-billion-dollar denervation market.

The newly issued patent expands and reinforces Autonomix's intellectual property estate related to real-time nerve sensing, mapping, physiological monitoring, and feedback-guided neuromodulation technologies. The patented systems and methods are designed to enable more precise targeting of autonomic nerves associated with a variety of chronic disease states, including hypertension, chronic heart failure, chronic renal failure, metabolic disorders, and other conditions linked to autonomic nervous system dysfunction and renal sympathetic nerve hyperactivity.

Unlike conventional denervation approaches that rely primarily on anatomical landmarks, the patented technology incorporates sensing-enabled devices capable of detecting neural and physiological responses in real time. This closed-loop approach may enable physicians to locate neural targets more accurately, assess treatment effects during therapy delivery, and evaluate procedural success through objective physiological feedback. Corresponding patents covering related inventions have previously been issued in the United States and Europe, reinforcing Autonomix's intellectual property position across major commercial markets.

Key Technologies Covered

The Canadian patent encompasses several core innovations in nerve-targeted therapy:

Brad Hauser, Chief Executive Officer of Autonomix, emphasized the strategic importance of the patent. "Securing this Canadian patent further strengthens our competitive position and expands the intellectual property foundation supporting our precision neuromodulation platform," said Hauser. "We believe the ability to identify, monitor and modulate neural targets using real-time physiological feedback may represent a transformational advancement in nerve-targeted therapy."

Autonomix is initially developing its platform for pain management, with early trials focused on pancreatic cancer. The company views the technology as a platform capable of addressing dozens of potential indications across cardiology, hypertension, and chronic pain.